This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the…
This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as "Doggybones." These linear constructs, which exclude unnecessary bacterial elements, demonstrated…
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Replacing plasmid DNA with enzymatically produced DNA in your AAV production eliminates many issues around complex or unstable sequences, purity, speed to manufacture, safety and scalability. Many biotech and pharma…
Discover how synthetic, backbone-free DNA offers a safer, scalable alternative to traditional plasmid DNA for AAV production, addressing key challenges in transfection efficiency, cost, and impurity control. Download the poster…
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Touchlight Wins ISPE Facility of the Year Award for Innovation, Recognised for Revolutionary dbDNA™ Manufacturing at Morelands Facility Published: 12 May 2025Touchlight, a pioneering leader in synthetic DNA technology, is…
Touchlight Appoints Industry Leader Will Downie as Adviser to Support Strategic Growth in Synthetic DNA Platforms Published: 27 January 2025 Touchlight Genetics, in partnership with the National Physical Laboratory (NPL)…
Ceva Animal Health and Touchlight sign an agreement to use Touchlight’s dbDNA technology in animal health Published: 16 January 2025 Ceva and Touchlight entered into an agreement and a long-term…